{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:50:06Z","timestamp":1794948606295,"version":"4.9.1"},"reference-count":280,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 EY010572"],"award-info":[{"award-number":["P30 EY010572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R013926\/1"],"award-info":[{"award-number":["MR\/R013926\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["216593\/Z\/19\/Z"],"award-info":[{"award-number":["216593\/Z\/19\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1803821N"],"award-info":[{"award-number":["1803821N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012618","name":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.preteyeres.2025.101354","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T20:16:24Z","timestamp":1741983384000},"page":"101354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy"],"prefix":"10.1016","volume":"106","author":[{"given":"Ryan","family":"Purdy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying Kai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Nerinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart P.","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Pennesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"MacLaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Dominik","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0065-9131","authenticated-orcid":false,"given":"Kanmin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2025.101354_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1184937","article-title":"CAR-Treg cell therapies and their future potential in treating ocular autoimmune conditions","volume":"3","author":"Abraham","year":"2023","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.672444","article-title":"Importance of autoimmune responses in progression of retinal degeneration initiated by gene mutations","volume":"8","author":"Adamus","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","article-title":"Systemic and local immune responses to intraocular AAV vector administration in non-human primates","volume":"24","author":"Ail","year":"2022","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000659","article-title":"Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness","volume":"2","author":"Amado","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of recombinant adeno-associated virus (AAV) vectors for gene transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.preteyeres.2025.101354_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.omtm.2021.10.010","article-title":"Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells","volume":"23","author":"Arjomandnejad","year":"2021","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1089\/hum.2014.057","article-title":"Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material","volume":"25","author":"Ayuso","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.01841","article-title":"Immune responses to influenza virus and its correlation to age and inherited factors","volume":"7","author":"Bahadoran","year":"2016","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib10","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib11","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in leber's congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib12","series-title":"Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Diabetic Retinopathy: the Phase II ALTITUDE\u00ae Study Dose Levels 1 and 2: One Year Results","author":"Barakat","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101354_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/hgtb.2016.039","article-title":"Effects of self-complementarity, codon optimization, transgene, and dose on liver transduction with AAV8","volume":"27","author":"Bell","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.preteyeres.2025.101354_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","article-title":"Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis","volume":"141","author":"Bellur","year":"2023","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101354_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.672449","article-title":"Effect of CpG depletion of vector genome on CD8+ T cell responses in AAV gene therapy","volume":"12","author":"Bertolini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib18","first-page":"4903","article-title":"Subretinal delivery of investigational ABBV-RGX-314 for neovascular age-related macular degeneration (nAMD): a phase II pharmacodynamic study","volume":"65","author":"Bhandari","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23098","article-title":"Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies","volume":"6","author":"Bitoun","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.preteyeres.2025.101354_bib20","first-page":"4537","article-title":"Impact of sequential bilateral intravitreal injection of rAAV2\/2-ND4 on ocular and systemic humoral immune status in non-human primates","volume":"59","author":"Bouquet","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune response and intraocular inflammation in patients with leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/gt.2016.31","article-title":"Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs","volume":"23","author":"Boyd","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib23","article-title":"Poly(ADP-Ribose) polymerases in host-pathogen interactions, inflammation, and immunity","volume":"83","author":"Brady","year":"2018","journal-title":"Microbiol. Mol. Biol. Rev.: MMBR (Microbiol. Mol. Biol. Rev.)"},{"key":"10.1016\/j.preteyeres.2025.101354_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors \u2013 implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib25","first-page":"5312","article-title":"Meta-analysis of gene therapy associated uveitis (GTAU)","volume":"65","author":"Buckley","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ophtha.2022.01.020","article-title":"Time to uveitis control with methotrexate and mycophenolate mofetil","volume":"129","author":"Bui","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid modifications for targeting and improving the efficacy of AAV vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib28","first-page":"352","article-title":"Phase 1 study of intravitreal gene therapy with ADVM-022 for neovascular AMD (OPTIC trial)","volume":"62","author":"Busbee","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2023.1272118","article-title":"Sex and gender affect immune aging","volume":"4","author":"Calabr\u00f2","year":"2023","journal-title":"Frontiers in Aging"},{"key":"10.1016\/j.preteyeres.2025.101354_bib30","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101354_bib31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate immune sensing of adeno-associated virus vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-017-8608-5","article-title":"Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases?","volume":"53","author":"Carvajal Alegria","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1270561","article-title":"Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology","volume":"3","author":"Carvalho","year":"2023","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib34","doi-asserted-by":"crossref","DOI":"10.3310\/WARA5730","article-title":"Gene therapy for choroideremia using an adeno-associated viral vector encoding Rab escort protein 1: the REGENERATE open-label trial","author":"Cehajic-Kapetanovic","year":"2024","journal-title":"Efficacy and Mech. Evaluation; National Institute for Health and Care Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib35","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Retinal gene therapy in X-linked retinitis pigmentosa caused by mutations in RPGR: results at 6 months in a first in human clinical trial","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2021.11.011","article-title":"First-in-Human robot-assisted subretinal drug delivery under local anesthesia","volume":"237","author":"Cehajic-Kapetanovic","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2020-000454","article-title":"Retinal detachment in retinitis pigmentosa","volume":"5","author":"Chan","year":"2020","journal-title":"BMJ Open Ophth"},{"key":"10.1016\/j.preteyeres.2025.101354_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.10.4.3","volume":"10","author":"Chan","year":"2021","journal-title":"Translational Vision Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib39","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.ymthe.2021.05.001","article-title":"Does systemic inflammation prompt gene therapy uveitis?","volume":"29","author":"Chan","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2021","journal-title":"J. Pediatr."},{"key":"10.1016\/j.preteyeres.2025.101354_bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omtm.2019.05.012","article-title":"Enhancement of adeno-associated virus-mediated gene therapy using hydroxychloroquine in murine and human tissues","volume":"14","author":"Chandler","year":"2019","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omtm.2021.05.011","article-title":"Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina","volume":"22","author":"Chandler","year":"2021","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib45","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1089\/hum.2022.159","article-title":"Update on viral gene therapy clinical trials for retinal diseases","volume":"33","author":"Cheng","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib47","first-page":"767","article-title":"Impact of differential sex response to the vector when developing IL-33 gene therapy for AMD","volume":"64","author":"Clare","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymthe.2025.01.028","article-title":"Characterisation of the ocular inflammatory response to AAV reveals divergence by sex and age","volume":"33","author":"Clare","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Cl\u00e9ment","year":"2016","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib50","first-page":"771","article-title":"Characterization of the limitations to gene transfer and associated inflammation following intravitreal AAV injection in nonhuman primates","volume":"57","author":"Comander","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib51","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.preteyeres.2025.101354_bib52","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ajpath.2011.10.008","article-title":"Therapeutic dosing of fingolimod (FTY720) prevents cell infiltration, rapidly suppresses ocular inflammation, and maintains the blood-ocular barrier","volume":"180","author":"Copland","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/iid3.404","article-title":"Age\u2010related differences in the immune response could contribute to determine the spectrum of severity of COVID\u201019","volume":"9","author":"Costagliola","year":"2021","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.preteyeres.2025.101354_bib54","article-title":"Laterally spreading AAV.SPR-hRS1 vector for treatment of XLRS","volume":"63","author":"Couto","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib55","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib56","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo\u2013directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib57","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/1673-5374.314309","article-title":"Small scale adeno-associated virus-vector production for preclinical gene delivery based on chloroform precipitation","volume":"17","author":"Davidsson","year":"2022","journal-title":"Neural Regeneration Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib58","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101354_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.19","article-title":"Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR","volume":"3","author":"D'Costa","year":"2016","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2024.108433","article-title":"The state of technological advancement to address challenges in the manufacture of rAAV gene therapies","volume":"76","author":"Destro","year":"2024","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.preteyeres.2025.101354_bib61","first-page":"1152","article-title":"Suprachoroidal delivery of RGX-314 for diabetic retinopathy: the phase II ALTITUDETM study","volume":"63","author":"Dhoot","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib62","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the center of the cell: tracing the path of AAV transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib63","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for UveitiS (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results after AAV2-mediated gene therapy for choroideremia: the alberta experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib65","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.2006.094698","article-title":"Mycophenolate mofetil in the treatment of uveitis in children","volume":"91","author":"Doycheva","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib66","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2025.101354_bib67","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41551-018-0248-4","article-title":"First-in-human study of the safety and viability of intraocular robotic surgery","volume":"2","author":"Edwards","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.preteyeres.2025.101354_bib69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.intimp.2014.12.021","article-title":"Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: an in-vitro study in healthy humans","volume":"24","author":"Fanigliulo","year":"2015","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib70","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.preteyeres.2025.101354_bib71","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/pr9081430","article-title":"Adenoviral vector COVID-19 vaccines: process and cost analysis","volume":"9","author":"Ferreira","year":"2021","journal-title":"Processes"},{"key":"10.1016\/j.preteyeres.2025.101354_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00082","article-title":"Immune responses to AAV-vectors, the Glybera example from bench to bedside","volume":"5","author":"Ferreira","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib73","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2013.169","article-title":"Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPLS447X) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy","volume":"25","author":"Ferreira","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib74","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hgtb.2016.086","article-title":"Evaluation of an optimized injection system for retinal gene therapy in human patients","volume":"27","author":"Fischer","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.preteyeres.2025.101354_bib75","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/j.ymthe.2017.05.005","article-title":"Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa","volume":"25","author":"Fischer","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib76","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","article-title":"Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial","volume":"138","author":"Fischer","year":"2020","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib77","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib78","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/biom14010122","article-title":"Real-world safety and effectiveness of voretigene neparvovec: results up to 2 Years from the prospective, registry-based PERCEIVE study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.preteyeres.2025.101354_bib80","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/mt.2008.186","article-title":"Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2\/8 gene transfer","volume":"16","author":"Foster","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib81","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: an evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ceo.13914","article-title":"Epiretinal membrane: a review","volume":"49","author":"Fung","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib83","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa","year":"2021","journal-title":"Drug Deliv. and Transl. Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib84","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","article-title":"Perifoveal chorioretinal atrophy after subretinal voretigene neparvovec-rzyl for RPE65-mediated leber congenital amaurosis","volume":"6","author":"Gange","year":"2022","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.preteyeres.2025.101354_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-4939-7522-8_12","article-title":"Optogenetic retinal gene therapy with the light gated GPCR vertebrate rhodopsin","volume":"1715","author":"Gaub","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial","volume":"20","author":"Gaudet","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib87","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum. Genet."},{"key":"10.1016\/j.preteyeres.2025.101354_bib88","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","volume":"16","author":"Ghoraba","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib89","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.omtm.2021.02.010","article-title":"Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies","volume":"20","author":"Gimpel","year":"2021","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib90","article-title":"Surgical procedure and applicability of the Orbit subretinal delivery system (SDS)TM in the normal adult canine eye","volume":"63","author":"Gray","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib91","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.4049\/jimmunol.1501723","article-title":"Treatment of uveitis by in situ administration of ex vivo\u2013activated polyclonal regulatory T cells","volume":"196","author":"Gr\u00e9goire","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib92","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1089\/hum.2019.277","article-title":"A novel next-generation sequencing and analysis platform to assess the identity of recombinant adeno-associated viral preparations from viral DNA extracts","volume":"31","author":"Guerin","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib93","article-title":"Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degeneration","author":"Hallam","year":"2024","journal-title":"medRxiv."},{"key":"10.1016\/j.preteyeres.2025.101354_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110848","article-title":"The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: inhibition of dendritic cell functions via Toll like receptor 9 signaling","volume":"132","author":"Han","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.preteyeres.2025.101354_bib95","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/eji.201545867","article-title":"Synergistic inhibition of PARP-1 and NF-\u03baB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy","volume":"46","author":"Hareendran","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib96","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1515\/BC.1999.118","article-title":"A role of poly (ADP-ribose) polymerase in NF-kappaB transcriptional activation","volume":"380","author":"Hassa","year":"1999","journal-title":"Biol. Chem."},{"key":"10.1016\/j.preteyeres.2025.101354_bib97","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib98","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101354_bib99","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/hep.24625","article-title":"Toll-like receptor 2\u2013mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors","volume":"55","author":"H\u00f6sel","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib101","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.11.3.13","article-title":"The learning curve of murine subretinal injection among clinically trained ophthalmic surgeons","volume":"11","author":"Huang","year":"2022","journal-title":"Translational Vision Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib102","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2023216118","article-title":"Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis","volume":"118","author":"Huang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.preteyeres.2025.101354_bib103","article-title":"Interim safety results in two phase 1\/2 open-label, dose-escalation clinical trials of subretinal gene therapy with AGTC-401 (rAAV2tYF-PR1.7-hCNGB3) and AGTC-402 (rAAV2tYF-PR1.7-hCNGA3) in subjects with achromatopsia (ACHM)","volume":"63","author":"Iannaccone","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib105","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41433-022-02262-5","article-title":"Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy","volume":"37","author":"Jalil","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2025.101354_bib106","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2020.06.038","article-title":"Retinal specialist versus artificial intelligence detection of retinal fluid from OCT","volume":"128","author":"Keenan","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib107","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ophtha.2022.06.018","article-title":"Inflammation after voretigene neparvovec administration in patients with RPE65-related retinal dystrophy","volume":"129","author":"Kessel","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib108","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1089\/hum.2018.144","article-title":"Dosage thresholds and influence of transgene cassette in adeno-associated virus\u2013related toxicity","volume":"29","author":"Khabou","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib109","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1002\/bit.26031","article-title":"Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8","volume":"113","author":"Khabou","year":"2016","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.preteyeres.2025.101354_bib110","series-title":"Subretinal Delivery of Investigational ABBV-RGX-314 as a Gene Therapy for nAMD: First Time Results of a Fellow Eye Bilateral Dosing Study","author":"Khanani","year":"2024"},{"key":"10.1016\/j.preteyeres.2025.101354_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102394","article-title":"Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study","volume":"67","author":"Khanani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.preteyeres.2025.101354_bib112","first-page":"5055","article-title":"Interim results for the Phase 1\/2 PRISM Trial evaluating 4D-150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration","volume":"64","author":"Khanani","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib113","first-page":"4356","article-title":"Interim results from the PRISM randomized phase 2 dose expansion trial evaluating 4D-150 in high anti-VEGF need individuals with neovascular (wet) age-related macular degeneration","volume":"65","author":"Khanani","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib114","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/pharmaceutics13010108","article-title":"Ocular drug delivery to the retina: current innovations and future perspectives","volume":"13","author":"Kim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101354_bib115","series-title":"Ixo-Vec Intravitreal Gene Therapy for Neovascular Age-Related Macular Degeneration","author":"Kiss","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101354_bib116","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/bies.201200099","article-title":"Sex influences immune responses to viruses, and efficacy of prophylaxis and therapeutic treatments for viral diseases","volume":"34","author":"Klein","year":"2012","journal-title":"Bioessays"},{"key":"10.1016\/j.preteyeres.2025.101354_bib117","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-023-04874-3","article-title":"Anti-human-TIGIT agonistic antibody ameliorates autoimmune diseases by inhibiting Tfh and Tph cells and enhancing Treg cells","volume":"6","author":"Kojima","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101309","article-title":"Characterization of AAV vectors: a review of analytical techniques and critical quality attributes","volume":"32","author":"Kontogiannis","year":"2024","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib120","author":"Kotterman"},{"key":"10.1016\/j.preteyeres.2025.101354_bib121","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/gt.2014.115","article-title":"Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates","volume":"22","author":"Kotterman","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.13.6.11","article-title":"Perimacular atrophy following voretigene neparvovec-rzyl treatment in the setting of previous contralateral eye treatment with a different viral vector","volume":"13","author":"Ku","year":"2024","journal-title":"Translational Vision Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib123","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","article-title":"Human T cell development, localization, and function throughout life","volume":"48","author":"Kumar","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.preteyeres.2025.101354_bib124","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1038\/s41467-024-51575-4","article-title":"Interim safety and efficacy of gene therapy for RLBP1-associated retinal dystrophy: a phase 1\/2 trial","volume":"15","author":"Kvanta","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2025.101354_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.846782","article-title":"Subretinal therapy: technological solutions to surgical and immunological challenges","volume":"9","author":"Ladha","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib126","first-page":"4485","article-title":"Defining parameters for robotic or manual reflux-free subretinal injections in an ex vivo animal model","volume":"61","author":"Ladha","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib127","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ajo.2022.02.023","article-title":"Leber hereditary optic neuropathy gene therapy: adverse events and visual acuity results of all patient groups","volume":"241","author":"Lam","year":"2022","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib129","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","article-title":"Assessment of visual function with cotoretigene toliparvovec in X-linked retinitis pigmentosa in the randomized XIRIUS phase 2\/3 study","volume":"131","author":"Lam","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib130","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1167\/iovs.15-17757","article-title":"In vitro and in vivo sustained zero-order delivery of rapamycin (sirolimus) from a biodegradable intraocular device","volume":"56","author":"Lance","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib131","first-page":"781","article-title":"Intravitreal AAV delivery causes long-term subclinical microglia activation in mice","volume":"64","author":"Langer","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib132","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 leber congenital amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib133","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.32","article-title":"Advanced characterization of DNA molecules in rAAV vector preparations by single-stranded virus next-generation sequencing","volume":"4","author":"Lecomte","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.preteyeres.2025.101354_bib134","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/bit.20562","article-title":"PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization","volume":"92","author":"Lee","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.preteyeres.2025.101354_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116148","article-title":"Novel chemical tyrosine functionalization of adeno-associated virus improves gene transfer efficiency in liver and retina","volume":"171","author":"Leray","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.preteyeres.2025.101354_bib136","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000526317","article-title":"Gene therapy for inherited retinal disease: long-term durability of effect","volume":"66","author":"Leroy","year":"2022","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib137","article-title":"Age-associated alterations in immune function and inflammation","volume":"118","author":"Lewis","year":"2022","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.preteyeres.2025.101354_bib138","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/mt.2010.46","article-title":"Regulation of retinal function but nonrescue of vision in RPE65-deficient dogs treated with doxycycline-regulatable AAV vectors","volume":"18","author":"Lh\u00e9riteau","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib139","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.preteyeres.2025.101354_bib140","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1136\/bjophthalmol-2018-311964","article-title":"Prevalence of cystoid macular oedema, epiretinal membrane and cataract in retinitis pigmentosa","volume":"103","author":"Liew","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib141","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.63.3.30","article-title":"Antimetabolite drugs exhibit distinctive immunomodulatory mechanisms and effects on the intestinal microbiota in experimental autoimmune uveitis","volume":"63","author":"Lloren\u00e7","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib142","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/hgtb.2013.131","article-title":"Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR","volume":"25","author":"Lock","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.preteyeres.2025.101354_bib143","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ophtha.2023.09.006","article-title":"Single center experience with voretigene neparvovec gene augmentation therapy in RPE65 mutation\u2013associated inherited retinal degeneration in a clinical setting","volume":"131","author":"Lorenz","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib144","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/membranes13090770","article-title":"Affinity and pseudo-affinity membrane chromatography for viral vector and vaccine purifications: a review","volume":"13","author":"Lothert","year":"2023","journal-title":"Membranes"},{"key":"10.1016\/j.preteyeres.2025.101354_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154943","article-title":"Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa","volume":"127","author":"Lu","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.preteyeres.2025.101354_bib146","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1038\/s41467-024-48221-4","article-title":"An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species","volume":"15","author":"Luo","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2025.101354_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.868448","article-title":"Exploring sex-related differences in microglia may Be a game-changer in precision medicine","volume":"14","author":"Lynch","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib148","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1089\/hum.2024.017","article-title":"An open-label phase II study assessing the safety of bilateral, sequential administration of retinal gene therapy in participants with choroideremia: the GEMINI study","volume":"35","author":"MacLaren","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib149","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1038\/s41591-023-02520-3","article-title":"Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial","volume":"29","author":"MacLaren","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib150","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101354_bib151","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.preteyeres.2025.101354_bib152","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib153","series-title":"Advances in Immunology","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0065-2776(08)60047-4","article-title":"Age influence on the immune system","author":"Makinodan","year":"1980"},{"key":"10.1016\/j.preteyeres.2025.101354_bib154","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/biom13020271","article-title":"Cellular and molecular mechanisms of pathogenesis underlying inherited retinal dystrophies","volume":"13","author":"Manley","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.preteyeres.2025.101354_bib155","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41467-020-14396-9","article-title":"Sexual-dimorphism in human immune system aging","volume":"11","author":"M\u00e1rquez","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2025.101354_bib156","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/genes12040601","article-title":"Accurate quantification of AAV vector genomes by quantitative PCR","volume":"12","author":"Martinez-Fernandez de la Camara","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.preteyeres.2025.101354_bib157","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9\u2013dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2025.101354_bib158","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73749-y","article-title":"Sectoral activation of glia in an inducible mouse model of autosomal dominant retinitis pigmentosa","volume":"10","author":"Massengill","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101354_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.570909","article-title":"Optogenetic gene therapy for the degenerate retina: recent advances","volume":"14","author":"McClements","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib160","first-page":"62","article-title":"Immunogenicity of Cas9 protein","volume":"109","author":"Mehta","year":"2020","journal-title":"JPharmSci"},{"key":"10.1016\/j.preteyeres.2025.101354_bib161","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IIO.0000000000000366","article-title":"Ocular inflammation and treatment emergent adverse events in retinal gene therapy","volume":"61","author":"Mehta","year":"2021","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.preteyeres.2025.101354_bib162","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.preteyeres.2025.101354_bib163","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.preteyeres.2025.101354_bib164","first-page":"7","article-title":"Advances in overcoming immune responses following hemophilia gene therapy","volume":"1","author":"Miao","year":"2011","journal-title":"J. Genet Syndr Gene Ther Suppl."},{"key":"10.1016\/j.preteyeres.2025.101354_bib165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2024.05.034","article-title":"Phase 1\/2 AAV5-hRKp.RPGR (botaretigene sparoparvovec) gene therapy: safety and efficacy in RPGR-associated X-linked retinitis pigmentosa","volume":"267","author":"Michaelides","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib166","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ajo.2023.05.009","article-title":"First-in-Human gene therapy trial of AAV8-hCARp.hCNGB3 in adults and children with CNGB3-associated achromatopsia","volume":"253","author":"Michaelides","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib167","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib168","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1\u2013mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.preteyeres.2025.101354_bib169","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/j.ymthe.2021.02.013","article-title":"Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I\/IIa gene therapy trial","volume":"29","author":"Mishra","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib170","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1089\/hum.2023.227","article-title":"Role of FoxP3+ regulatory T cells in modulating immune responses to adeno-associated virus gene therapy","volume":"35","author":"Mu\u00f1oz-Melero","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib171","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/phar.2716","volume":"42","author":"Nelson","year":"2022","journal-title":"J. Human Pharmacol. Drug Therapy"},{"key":"10.1016\/j.preteyeres.2025.101354_bib172","first-page":"3854","article-title":"Rhesus macaque model of Bardet-Biedl syndrome: progression and response to gene therapy","volume":"64","author":"Neuringer","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib173","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/brain\/awac421","article-title":"Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy","volume":"146","author":"Newman","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.preteyeres.2025.101354_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101289","article-title":"Genetic therapies and potential therapeutic applications of CRISPR activators in the eye","volume":"102","author":"Ng","year":"2024","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib175","first-page":"1504","article-title":"Preliminary results from a first-in-human phase I\/II gene therapy study (FOCUS) of subretinally delivered GT005, an investigational AAV2 vector, in patients with geographic atrophy secondary to age-related macular degeneration","volume":"63","author":"Nielsen","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib176","first-page":"A479","article-title":"The influence of sex and gender on the immune response","volume":"11","author":"Oertelt-Prigione","year":"2012","journal-title":"Autoimmunity Reviews, Special Issue on Gender, Sex Hormones, Pregnancy and Autoimmunity"},{"key":"10.1016\/j.preteyeres.2025.101354_bib177","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/IAE.0000000000001029","article-title":"Novel technique for subretinal injection using local removal of the internal limiting membrane","volume":"36","author":"Okanouchi","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101354_bib178","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.61.11.30","article-title":"Changes of serum inflammatory molecules and their relationships with visual function in retinitis pigmentosa","volume":"61","author":"Okita","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib179","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1073\/pnas.1820387116","article-title":"Retinal microglia initiate neuroinflammation in ocular autoimmunity","volume":"116","author":"Okunuki","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.preteyeres.2025.101354_bib180","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3390\/ijms22042096","article-title":"Retinal inflammation, cell death and inherited retinal dystrophies","volume":"22","author":"Olivares-Gonz\u00e1lez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib181","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-021-02709-2","article-title":"Acazicolcept (ALPN-101), a dual ICOS\/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models","volume":"24","author":"Orvain","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib182","first-page":"184","article-title":"Age-associated decrease in toll-like receptor function in primary human dendritic cells predicts influenza vaccine response","author":"Panda","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib183","first-page":"5327","article-title":"Six-year results of a Phase I\/IIa gene therapy trial in patients with Usher Syndrome Type-1B (USH1B)","volume":"65","author":"Parker","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib184","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.924267","article-title":"Individuals with higher CD4\/CD8 ratio exhibit increased risk of acute respiratory distress syndrome and in-hospital mortality during acute SARS-CoV-2 infection","volume":"9","author":"Pascual-Dapena","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00844","article-title":"Efficient capsid antigen presentation from adeno-associated virus empty virions in vivo","volume":"9","author":"Pei","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib186","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/hgtb.2016.185","article-title":"Accurate identification and quantification of DNA species by next-generation sequencing in adeno-associated viral vectors produced in insect cells","volume":"28","author":"Penaud-Budloo","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.preteyeres.2025.101354_bib187","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.oret.2022.06.013","article-title":"Intravitreal delivery of rAAV2tYF-CB-hRS1 vector for gene augmentation therapy in patients with X-linked retinoschisis: 1-year clinical results","volume":"6","author":"Pennesi","year":"2022","journal-title":"Ophthalmology Retina"},{"key":"10.1016\/j.preteyeres.2025.101354_bib188","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/brainsci10020119","article-title":"Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib189","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib190","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","article-title":"Adalimumab drug monitoring and treatment adjustment to drug antibodies in noninfectious uveitis","volume":"268","author":"Pichi","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib191","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012693","article-title":"Sex difference leads to differential gene expression patterns and therapeutic efficacy in mucopolysaccharidosis IVA murine model receiving AAV8 gene therapy","volume":"23","author":"Piechnik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib192","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene editing for cep290-associated retinal degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib193","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/antiox11061086","article-title":"Inherited retinal dystrophies: role of oxidative stress and inflammation in their physiopathology and therapeutic implications","volume":"11","author":"Pinilla","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.preteyeres.2025.101354_bib194","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune responses and immunosuppressive strategies for adeno-associated virus-based gene therapy for treatment of central nervous system disorders: current knowledge and approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1089\/hum.2020.231","article-title":"Genome-editing strategies for treating human retinal degenerations","volume":"32","author":"Quinn","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib196","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68401-y","article-title":"Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis","volume":"14","author":"Quinn","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101354_bib197","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3390\/pharmaceutics15051484","article-title":"Delivery systems in ocular retinopathies: the promising future of intravitreal hydrogels as sustained-release scaffolds","volume":"15","author":"Rafael","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101354_bib198","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0140-6736(15)00345-1","article-title":"Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial","volume":"386","author":"Rakoczy","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101354_bib199","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/hum.2016.111","article-title":"Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina","volume":"28","author":"Ramachandran","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib200","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib201","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib202","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101354_bib203","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/archopht.126.10.1390","article-title":"Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease","volume":"126","author":"Raveney","year":"2008","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib204","series-title":"Suprachoroidal Delivery of Investigational ABBV-RGX-314 for Neovascular AMD: Results from the Phase II AAVIATE Study","year":"2024"},{"key":"10.1016\/j.preteyeres.2025.101354_bib208","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.ymthe.2017.08.018","article-title":"AAV8 can induce innate and adaptive immune response in the primate eye","volume":"25","author":"Reichel","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib209","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/bjophthalmol-2021-319067","article-title":"Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial","volume":"106","author":"Reichel","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib210","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1167\/iovs.17-22494","article-title":"Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients","volume":"59","author":"Reichel","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib211","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/bjophthalmol-2021-321023","article-title":"Development of retinal atrophy after subretinal gene therapy with voretigene neparvovec","volume":"107","author":"Reichel","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100050","article-title":"An optimized treatment protocol for subretinal injections limits intravitreal vector distribution","volume":"1","author":"Reichel","year":"2021","journal-title":"Ophthalmology Science"},{"key":"10.1016\/j.preteyeres.2025.101354_bib213","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29726-7","article-title":"Development of an inducible anti-VEGF rAAV gene therapy strategy for the treatment of wet AMD","volume":"8","author":"Reid","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101354_bib214","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3390\/pharmaceutics14091973","article-title":"Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy","volume":"14","author":"Ren","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101354_bib215","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.4049\/jimmunol.169.9.4697","article-title":"Cutting edge: impaired toll-like receptor expression and function in aging","volume":"169","author":"Renshaw","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib216","series-title":"Ophthalmic Product Development: from Bench to Bedside","first-page":"613","article-title":"Manufacturing considerations and challenges for AAV ocular gene therapy","author":"Rodrigues","year":"2021"},{"key":"10.1016\/j.preteyeres.2025.101354_bib217","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","article-title":"Pharmaceutical development of AAV-based gene therapy products for the eye","volume":"36","author":"Rodrigues","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib218","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.10.6.15","article-title":"Longitudinal evaluation of hyper-reflective foci in the retina following subretinal delivery of adeno-associated virus in non-human primates","volume":"10","author":"Rodr\u00edguez-Bocanegra","year":"2021","journal-title":"Translational Vision Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib219","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10633-017-9605-y","article-title":"Unilateral cancer-associated retinopathy: diagnosis, serology and treatment","volume":"135","author":"Roels","year":"2017","journal-title":"Doc. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib220","first-page":"1","article-title":"Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection","author":"Ross","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib221","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.preteyeres.2025.101354_bib222","doi-asserted-by":"crossref","DOI":"10.1038\/srep39537","article-title":"Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration","volume":"6","author":"Sahaboglu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.preteyeres.2025.101354_bib223","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib224","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3390\/pharmaceutics14091842","article-title":"Non-viral delivery of CRISPR\/Cas cargo to the retina using nanoparticles: current possibilities, challenges, and limitations","volume":"14","author":"Salman","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.preteyeres.2025.101354_bib225","series-title":"Viruses in Human Gene Therapy","first-page":"53","article-title":"Adeno-associated viral vectors","author":"Samulski","year":"1995"},{"key":"10.1016\/j.preteyeres.2025.101354_bib226","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1006\/mthe.2001.0308","article-title":"Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina","volume":"3","author":"Sanftner","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib227","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1177711","article-title":"The double-edged sword of inflammation in inherited retinal degenerations: clinical and preclinical evidence for mechanistically and prognostically impactful but treatable complications","volume":"11","author":"Sarici","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib228","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41434-021-00294-2","article-title":"Injection pressure levels for creating blebs during subretinal gene therapy","volume":"29","author":"Scruggs","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib229","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1167\/iovs.17-22473","article-title":"Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates","volume":"58","author":"Seitz","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2024.100516","article-title":"Dose-dependent progression of chorioretinal atrophy at the injection site after subretinal injection of rAAV2\/8 in nonhuman primates","volume":"4","author":"Seitz","year":"2024","journal-title":"Ophthalmology Science"},{"key":"10.1016\/j.preteyeres.2025.101354_bib231","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1021\/ja502616y","article-title":"Defining the stoichiometry and cargo load of viral and bacterial nanoparticles by orbitrap mass spectrometry","volume":"136","author":"Snijder","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.preteyeres.2025.101354_bib232","series-title":"Regenerative Medicine for Degenerative Muscle Diseases","first-page":"21","article-title":"An overview of rAAV vector product development for gene therapy","author":"Snyder","year":"2016"},{"key":"10.1016\/j.preteyeres.2025.101354_bib233","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.xphs.2024.03.024","article-title":"Drug product formulation and fill\/finish manufacturing process considerations for AAV-based genomic Medicines","volume":"113","author":"Som","year":"2024","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib234","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ymthe.2005.12.001","article-title":"Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors","volume":"13","author":"Stieger","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib235","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ophtha.2023.02.015","article-title":"Full-field scotopic threshold improvement after voretigene neparvovec-rzyl treatment correlates with chorioretinal atrophy","volume":"130","author":"Stingl","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib236","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1080\/02713683.2024.2343335","article-title":"Feasibility of direct vitrectomy-sparing subretinal injection for gene delivery in large animals","volume":"49","author":"Stranak","year":"2024","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101354_bib237","article-title":"Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type-I interferon pathway","volume":"339","author":"Sun","year":"2012","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.preteyeres.2025.101354_bib239","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.13.8.18","article-title":"Ocular and serum profiles of inflammatory molecules associated with retinitis pigmentosa","volume":"13","author":"Tao","year":"2024","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.preteyeres.2025.101354_bib240","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/aos.13899","article-title":"Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract","volume":"97","author":"ten Berge","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib241","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1167\/iovs.18-24333","article-title":"Surgical removal of internal limiting membrane and layering of AAV vector on the retina under air enhances gene transfection in a nonhuman primate","volume":"59","author":"Teo","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib242","doi-asserted-by":"crossref","first-page":"7171","DOI":"10.4049\/jimmunol.176.12.7171","article-title":"Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal Neoantigen1","volume":"176","author":"Terrada","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib243","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1089\/hum.2019.144","article-title":"Ocular inflammatory response to intravitreal injection of adeno-associated virus vector: relative contribution of genome and capsid","volume":"31","author":"Timmers","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib244","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039853","article-title":"Sex differences in the response to viral infections: TLR8 and TLR9 ligand stimulation induce higher IL10 production in males","volume":"7","author":"Torcia","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.preteyeres.2025.101354_bib245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib246","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.62.2.41","article-title":"Characterization of gene therapy associated uveitis following intravitreal adeno-associated virus injection in mice","volume":"62","author":"Tummala","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib247","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib248","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.13862","article-title":"Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab","volume":"45","author":"Ungar","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib249","series-title":"Interim Subretinal Gene Therapy Safety Results in Two Phase 1\/2 Open-Label, Dose-Escalation Clinical Trials to Treat Achromatopsia - Presentation at","author":"Vajzovic","year":"2022"},{"key":"10.1016\/j.preteyeres.2025.101354_bib250","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3390\/ijms25021267","article-title":"The road towards gene therapy for X-linked juvenile retinoschisis: a systematic review of preclinical gene therapy in cell-based and rodent models of xlrs","volume":"25","author":"van der Veen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib251","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib252","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/hum.2023.191","article-title":"Peripheral cellular immune responses induced by subretinal adeno-associated virus gene transfer can Be restrained by the subretinal-associated immune inhibition mechanism","volume":"35","author":"Vendom\u00e8le","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib253","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00504","article-title":"Subretinal injection of HY peptides induces systemic antigen-specific inhibition of effector CD4+ and CD8+ T-cell responses","volume":"9","author":"Vendom\u00e8le","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib254","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","article-title":"Safety of rAAV2\/2-ND4 gene therapy for leber hereditary optic neuropathy","volume":"125","author":"Vignal-Clermont","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib255","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ajo.2022.11.026","article-title":"Safety of lenadogene nolparvovec gene therapy over 5 Years in 189 patients with leber hereditary optic neuropathy","volume":"249","author":"Vignal-Clermont","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib256","first-page":"1","article-title":"Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib257","first-page":"1","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib258","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.omtm.2020.09.017","article-title":"A qPCR method for AAV genome titer with ddPCR-level of accuracy and precision","volume":"19","author":"Wang","year":"2020","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib259","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.omtm.2019.08.011","article-title":"Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates","volume":"15","author":"Weed","year":"2019","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib260","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 Years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood\u2013onset retinal dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib261","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hgtb.2015.013","article-title":"Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products","volume":"26","author":"Werling","year":"2015","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.preteyeres.2025.101354_bib262","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/09273948.2018.1529800","article-title":"Efficacy of high-dose methotrexate in pediatric non-infectious uveitis","volume":"27","author":"Wieringa","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101354_bib263","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/hum.2022.222","article-title":"The degree of adeno-associated virus-induced retinal inflammation varies based on serotype and route of delivery: intravitreal, subretinal, or suprachoroidal","volume":"34","author":"Wiley","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib264","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00261","article-title":"Immunology of AAV-mediated gene transfer in the eye","volume":"4","author":"Willett","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib265","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.12.3.27","article-title":"Systemic administration of acazicolcept, a dual CD28 and inducible T cell costimulator inhibitor, ameliorates experimental autoimmune uveitis","volume":"12","author":"Wilson","year":"2023","journal-title":"Translational Vision Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib266","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/IAE.0000000000002669","article-title":"Nanovitreoretinal subretinal Gateway device to displace submacular hemorrhage: access to the subretinal space without vitrectomy","volume":"42","author":"Wood","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101354_bib267","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2020.01.026","article-title":"Codon modification and PAMPs in clinical AAV vectors: the tortoise or the hare?","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib268","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/biomedicines2010080","article-title":"Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment","volume":"2","author":"Wright","year":"2014","journal-title":"Biomedicines"},{"key":"10.1016\/j.preteyeres.2025.101354_bib269","doi-asserted-by":"crossref","DOI":"10.1126\/science.1229963","article-title":"Cyclic-GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA","volume":"339","author":"Wu","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.preteyeres.2025.101354_bib270","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib271","series-title":"Subretinal Delivery of RGX-314 for Neovascular AMD: A Phase II Pharmacodynamic Study","author":"Wykoff","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101354_bib272","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ymthe.2019.11.014","article-title":"The effect of CpG sequences on capsid-specific CD8+ T cell responses to AAV vector gene transfer","volume":"28","author":"Xiang","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101354_bib273","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1073\/pnas.1821000116","article-title":"AAV cis-regulatory sequences are correlated with ocular toxicity","volume":"116","author":"Xiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.preteyeres.2025.101354_bib274","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2025.101354_bib275","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib276","article-title":"18 Month analysis of macular structure using optical coherence tomography (OCT) from a phase 1\/2 clinical study of subretinal gene therapy drug AGTC-501 for X-linked retinitis pigmentosa","volume":"63","author":"Yang","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101354_bib277","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041305","article-title":"Immunology of retinitis pigmentosa and gene therapy-associated uveitis","volume":"14","author":"Yang","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.preteyeres.2025.101354_bib278","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0140-6736(24)01447-8","article-title":"Safety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1\/2, multicentre, open-label, unilateral dose escalation study","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.preteyeres.2025.101354_bib279","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","article-title":"Compartmentalized ocular lymphatic system mediates eye\u2013brain immunity","volume":"628","author":"Yin","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.preteyeres.2025.101354_bib280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol. Therapy Methods Clin. Dev."},{"key":"10.1016\/j.preteyeres.2025.101354_bib281","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-021-04345-x","article-title":"Local and systemic responses to SARS-CoV-2 infection in children and adults","volume":"602","author":"Yoshida","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.preteyeres.2025.101354_bib282","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2012.07.006","article-title":"Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa","volume":"120","author":"Yoshida","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101354_bib283","first-page":"659","article-title":"Rapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1\/Th2\/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells","volume":"8","author":"Yuan","year":"2015","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101354_bib284","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101354_bib285","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/ange.201814275","article-title":"Proactively reducing anti-drug antibodies via immunomodulatory bioconjugation","volume":"131","author":"Zhang","year":"2019","journal-title":"Angew. Chem."},{"key":"10.1016\/j.preteyeres.2025.101354_bib286","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.preteyeres.2025.101354_bib287","doi-asserted-by":"crossref","unstructured":"Tan, Q., Liu, H., Bian, B., Liu, Y., 2023. The sexed retina: a combined single-cell and bulk RNA sequencing analysis of healthy aging human retina. doi: 10.21203\/rs.3.rs-3365102\/v1.","DOI":"10.21203\/rs.3.rs-3365102\/v1"}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946225000278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946225000278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:02:17Z","timestamp":1764043337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946225000278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":280,"alternative-id":["S1350946225000278"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101354","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101354"}}